NEXIGN
26.10.2021 09:02:17 CEST | Business Wire | Press release
Nexign (part of ICS Holding), an international provider of business support systems (BSS), has announced it won the MEA Technology Achievement Award and was shortlisted for another prestigious international award for the telecom industry, Glotel .
The MEA Tech Award was introduced by the MEA Business magazine, one of the business's top publications in the Middle East and Africa, while the Global Telecom Award brings together the top players in telecom from around the world recognizing innovation and excellence.
The prize and the nomination were awarded the same week for the Nexign Microservices Platform and the Microservices Factory project based on it.
Nexign Microservices Platform supports the whole cycle of development and delivery based on cloud-native microservices architecture, which lays the foundation for continuous creation of new digital services. The framework leverages CI/CD automation and facilitates partner collaboration through standardised APIs. This solution enabled the launch of Microservices Factory at MegaFon and allowed the company to reduce TTM for internal innovations. Nexign Microservices Framework empowered MegaFon to roll out 100+ new services, bring to market a multi-subscription digital services platform MegaFon Plus, and generally slash TTM from 3-4 months up to 2 weeks.
The project resulted in building the Open Ecosystem, constantly expanding with the new partners enriching MegaFon’s portfolio with the new product offerings. Nexign Microservices Platform enables telecom operators to always stay at the forefront of market changes and steadily cater to the ever-changing needs of its customers.
Both the development project and the final product have garnered recognition from the international telecom industry, to which the MEA Tech Award and the Glotel nomination are a token.
“The award and the nomination are not just a huge honour for Nexign. They signify the professional community’s recognition and appreciation of our projects. We strongly believe the Microservices Platform is a solution the world of telecom really needs these days. It would allow CSPs to swiftly react to any challenges the market can throw at them,” says Dmitry Antipov, the Customer Relations Director at Nexign.
About Nexign
Nexign (a part of Intellectual Computer Systems Holding (ICS Holding) is a major supplier of BSS solutions for telecom operators across 17 countries. The company focuses on modernising CSP’s IT systems to boost their profitability and slash TTM for new products.
Over 30 years on the market, Nexign has created an extensive suite of technological solutions to support and sustain transformation of telecom operators. Nexign’s products range from convergent BSS systems to elaborate optimisation solutions for subordinate software. Nexign boasts its comprehensive approach to reorganising all kinds of processes in the telecom industry, which offers a fresh impetus to the customer business and encourages innovations.
For more information, please visit the website and follow the latest news from Nexign on Twitter , Facebook and LinkedIn .
About ICS Holding
Intellectual Computer Systems Holding (https://x-holding.ru/ ) is a multidisciplinary Russian IT group, which holds a leading position in the technology and IT services development market. ICS Holding is the largest IT provider for telecom operators and one of the fastest growing IT holdings in the Russian market. ICS Holding is among Russia’s top three largest IT development companies, top ten IT companies and top ten suppliers of equipment for the industrial sector. The holding brings together more than 30 companies united in five subholdings: YADRO, Nexign, Citadel, Kryptonit and Forpost.
ICS Holding’s top priorities include the digital transformation of enterprise companies, information security, data storage systems, cryptography and quantum computing, machine learning and artificial neural networks, blockchain technology and artificial intelligence (AI). In terms of geographical reach, the business covers all regions of Russia, as well as several countries in the CIS and further afield.
ICS Holding companies employ in excess of 6,000 people. More than 120 global projects have been implemented in Russia and worldwide. More than 1000 of ICS Holding’s customers work in more than 20 countries.
The total revenue of ICS Holding companies in 2020 reached 85 billion rubles. The partner network of ICS Holding includes more than 50 companies in Russia and beyond.
15.09.2020 ICS Holding became a part of USM Telecom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005212/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
